News
EXAS
63.48
+0.41%
0.26
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
NASDAQ · 12h ago
Analysts Anticipate 12% Gains Ahead For The Holdings of VONG
NASDAQ · 16h ago
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
NASDAQ · 1d ago
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
NASDAQ · 1d ago
Notable Tuesday Option Activity: X, SPHR, EXAS
NASDAQ · 2d ago
Exact Sciences Appoints Aaron Bloomer as New CFO
TipRanks · 3d ago
Exact Sciences Appoints Aaron Bloomer As Chief Financial Officer
NASDAQ · 3d ago
Exact Sciences names Aaron Bloomer as CFO
Exact Sciences names Aaron Bloomer as chief financial officer. Bloomer previously held leadership positions at Baxter International and 3M. Exact Sciences will succeed Jeff Elliott as CFO effective May 15, 2024. The company is a subsidiary of healthcare company Exact Pharmaceuticals.
Seeking Alpha · 3d ago
Exact Sciences Taps Aaron Bloomer as Finance Chief
Exact Sciences names Aaron Bloomer as finance chief, replacing Jeff Elliott in the role. Bloomer most recently worked at Baxter International and spent a decade at 3M. Exact Sciences is a provider of cancer screening and diagnostic tests. Elliott said he planned to step down in 2024 due to personal reasons.
Dow Jones · 3d ago
Weekly Report: what happened at EXAS last week (0408-0412)?
Weekly Report · 3d ago
Exact Sciences Appoints Aaron Bloomer As CFO, Effective May 15, 2024
Benzinga · 3d ago
*Exact Sciences: Bloomer to Succeed Jeff Elliott Following Transition Period >EXAS
Dow Jones · 3d ago
EXACT SCIENCES - BLOOMER JOINS AS EXECUTIVE VICE PRESIDENT, FINANCE, EFFECTIVE IMMEDIATELY, WILL SUCCEED JEFF ELLIOTT AFTER 30-DAY TRANSITION PERIOD
Reuters · 3d ago
*Exact Sciences Names Aaron Bloomer As New Chief Financial Officer >EXAS
Dow Jones · 3d ago
Exact Sciences announces debt exchange transaction
Exact Sciences announces debt exchange transaction. Exact Sciences Corporation (EXAS) Stock is down 1.7% to $7.05. The company entered into privately negotiated exchange and purchase agreements with certain holders of the company’s convertible senior notes due 2028.
Seeking Alpha · 04/11 19:05
Myriad Genetics (MYGN) Announces Favorable Research Results
NASDAQ · 04/11 14:00
Zacks Investment Ideas feature highlights: Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies
NASDAQ · 04/11 11:52
*Exact Sciences: To Issue to Holders $620.7M of New Series of 1.75% Convertible Senior Notes Due 2031 in Exchange for Retirement of $359.7M of Holders' Existing Notes, and Payment to Co of About $266.8M Cash >EXAS
Dow Jones · 04/11 10:02
EXACT SCIENCES: CO AGREED TO ISSUE TO HOLDERS $620.7 MLN AGGREGATE PRINCIPAL AMOUNT OF A NEW SERIES OF 1.75% CONVERTIBLE SENIOR NOTES DUE 2031
Reuters · 04/11 10:00
*Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
Dow Jones · 04/11 10:00
More
Webull provides a variety of real-time EXAS stock news. You can receive the latest news about Exact Sciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About EXAS
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.